LETTERS

Cladribine in the treatment of systemic lupus erythematosus nephritis

Systemic lupus erythematosus (SLE) nephritis often requires treatment with cyclophosphamide, which carries the risk of major side effects including infection, ovarian failure and bladder malignancy. Therapeutic strategies that would specifically target lymphocytes are appealing. Following the first report of the use of the purine nucleoside analogue cladribine (2-chloro-2’-deoxyadenosine), a selective lymphocyte depleting agent, in the treatment of lupus nephritis,1 we report our experience in two patients with severe renal involvement.

CASE 1
A 32 year old woman was diagnosed with SLE at age 28, with polyarthropathy, photosensitive rash, subcutaneous nodules, fatigue and lymphopenia. ANA, anti-dsDNA, anti-Sm and anti-RNP antibodies were present. Various immunosuppressants and corticosteroids failed to maintain a sustained remission. Two and a half years after presentation, she developed haematuria and proteinuria and renal biopsy revealed WHO Class III lupus nephritis. Treatment with pulsed intravenous cyclophosphamide and methylprednisolone had to be stopped after four months and a total cyclophosphamide dose of 9 g because of an anaphylactic reaction during an infusion. Despite azathioprine, 150 mg/day, and prednisolone, up to 20 mg/day, she developed severe hypertension (210/120 mm Hg) and biopsy confirmed lymphocytic cutaneous vasculitis. Cladribine (0.05 mg/kg/day for seven days as continuous intravenous infusion) and prednisolone 40 mg/day proved ineffective as creatinine rose from 149 to 243 µmol/l in two months. She also developed a perineal herpes simplex infection but drug was otherwise well tolerated. Pulse intravenous cyclophosphamide and methylprednisolone were subsequently reintroduced and creatinine has again fallen to 118 µmol/l.

Table 1 shows the results of investigations before and after cladribine infusions for both cases.

In the initial study by Davis et al.,3 three of seven patients treated with continuous cladribine infusion for a week responded completely and renal function did not deteriorate in any of the seven patients. Our limited experience suggests that cladribine may be effective in other manifestations of SLE (that is, cutaneous vasculitis), but it does not seem to have a consistent effect in severe nephritis. Good tolerability of the drug was confirmed and although herpes simplex infections occurred in both patients the role of corticosteroids cannot be ignored.

Further studies are required to establish the position of cladribine in the treatment of SLE especially in the presence of other lymphocyte depleting agents such as mycophenolate mofetil, which is reported to be effective in lupus nephritis,4 even in cases refractory to cyclophosphamide.

VLASSIS KONTOGIANNIS
PETER C LANYON
RICHARD J POWELL
Clinical Immunology Unit, University Hospital, Queen’s Medical Centre, Nottingham NG7 2UH

Correspondence to: Dr V Kontogiannis.

Table 1 Results of investigations before and after cladribine infusions

<table>
<thead>
<tr>
<th>Patient 1</th>
<th>First infusion</th>
<th>Second infusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Before</td>
<td>After</td>
<td>Before</td>
</tr>
<tr>
<td>Proteinuria</td>
<td>12.25 g/24 h</td>
<td>4.2 g/24 h</td>
</tr>
<tr>
<td>Serum creatinine</td>
<td>190 µmol/l</td>
<td>120 µmol/l</td>
</tr>
<tr>
<td>Anti-ds DNA</td>
<td>132 IU/ml</td>
<td>58 IU/ml</td>
</tr>
<tr>
<td>C3</td>
<td>0.51 g/l</td>
<td>0.67 g/l</td>
</tr>
<tr>
<td>C4</td>
<td>0.13 g/l</td>
<td>0.14 g/l</td>
</tr>
<tr>
<td>C5</td>
<td>22 units/ml</td>
<td>10 units/ml</td>
</tr>
<tr>
<td>Urine analysis</td>
<td>red cells, hyalurgranular, cellular casts</td>
<td>15 units/ml</td>
</tr>
</tbody>
</table>

Reference ranges: serum creatinine 50–100 µmol/l, anti-dsDNA: 50–300 IU/ml positive, >300 IU/ml strongly positive, C3: 0.63–1.19 g/l, C4: 0.11–0.43 g/l, C3d: up to 12 units/ml

Leg bone pain syndrome in a kidney transplant patient treated with tacrolimus (FK506)

Patients with chronic renal failure often develop musculoskeletal problems such as renal osteodystrophy and amyloid arthropathy1 and in successful renal transplantation other complications may ensue, particularly avascular necrosis.2 Since the availability of immunosuppressive agents for rejection, there has been a decrease in musculoskeletal problems, however, new complications have been described such as a symmetrical bone pain syndrome and reflex sympathetic dystrophy syndrome (RSDS), some of them related to cyclosporin.3

Tacrolimus is a novel macrolide with potent immunosuppressive effects and with a very similar mechanism of action to cyclosporine A—that is, calcineurin phosphatase inhibition.4 We report on a patient treated with tacrolimus, who developed a leg bone pain syndrome, two months after kidney transplantation.

The patient was a 50 year old woman with severe hypertension, treated with atenolol (100 mg/day), verapamil (240 mg/day) and clonidine (0.150 mg/day). She developed chronic renal failure and was treated with peritoneal dialysis in 1995. In 1997 she underwent a kidney transplant from a cadaver and immunosuppressive treatment with tacrolimus (4 mg/day) and prednisone (15 mg/day) was started. Two months after transplantation she reported progressive bilateral symmetric pain in the knees. Because of pain and difficulty in walking she was readmitted to our unit. At this time, the patient was receiving tacrolimus (4 mg/day) and prednisone (5 mg/day). Clinical examination revealed pain on movement and tenderness over the bone and joint line, without swelling.

Reference ranges: serum creatinine 50–100 µmol/l, anti-dsDNA: 50–300 IU/ml positive, >300 IU/ml strongly positive, C3: 0.63–1.19 g/l, C4: 0.11–0.43 g/l, C3d: up to 12 units/ml

or increased temperature. She had no signs of autonomic vaso-motor disturbances and ar- terial mobility was normal. Examination of the remaining peripheral and axial joints was normal.

Blood tests showed creatinine levels of 1.3 mg/dl, calcium of 10.1 mg/dl, phosphate of 3.5 mg/dl and urate of 7.2 mg/dl. Other labor- tory findings were normal. Patchy oste- oporosis in the knees was seen radiographi- cally. Bone scintigraphy showed intense uptake in both the osseous and vascular phases in the knees (fig 1). Calcitonin treatment was begun (three monthly cycles of 10 intramuscular units/day during 20 days) without clinical improvement. Because of the high serum concentrations of tacrolimus (15 µg/ml) and the ineffective calcitonin treat- ment, tacrolimus was reduced to 2 mg/day. Nine months after transplantation, she was free of symptoms and radiographs and tacrolimus concentration (9.1 µg/ml) were normal. Changes in plasma tacrolimus con- centrations subsequent to the resolution of symptoms did not occur and the patient con- tinued asymptomatic.

We describe a complication in a patient treated with tacrolimus after kidney trans- plantation that is similar to that described by other authors in transplanted patients treated with cyclosporin. Although the radiographic and bone scintigraphy findings suggested RSDS, the symptoms of this patient were not the classic features of this entity. The efficacy of corticosteroids in the treatment of uncom- plicated RSDS has been demonstrated, therefore it is possible that corticosteroids might have a protective role against a full RSDS develop- ment, as she was treated with high doses of prednisone after the renal transplantation.

The early onset of symptoms after the administration of the drug and the clinical improvement after the reduction of the immunosuppressant dose, are features that support a possible relation between tac- rolimus and the leg bone pain syndrome. The patient had high plasma tacrolimus concen- trations at the onset of the clinical symptoms and the improvement appeared only when the drug doses went down. Although recurrence of knee symptoms with an increase in tacrolimus dose would be much stronger proof of this association, it is not ethically justifiable. Furthermore, she was treated with verapamil in addition to other drugs for con- trolling hypertension. Verapamil might have played a part in a possible increased risk for this clinical complication, because it de- creases tacrolimus clearance. However, there are reports that calcium channel block- ers (albeit of the dihydropyridine type) can improve the bone pain syndrome.45

Although leg bone pain syndrome in kidney transplant patients who have received cyclosporin A is very rare, there are case reports described in the literature. To our knowledge, this is the first case of a renal transplant patient with pain in the lower limbs, related to tacrolimus treatment. Addi- tional case reports are needed to support this association.

Figure 1 Bone scintigraphy, showing increased uptake in both knees.


definition of corticosteroids in the treatment of uncom- plicated RSDS, the symptoms of this patient were not the classic features of this entity. The efficacy of corticosteroids in the treatment of uncom- plicated RSDS has been demonstrated, therefore it is possible that corticosteroids might have a protective role against a full RSDS develop- ment, as she was treated with high doses of prednisone after the renal transplantation.

The early onset of symptoms after the administration of the drug and the clinical improvement after the reduction of the immunosuppressant dose, are features that support a possible relation between tac- rolimus and the leg bone pain syndrome. The patient had high plasma tacrolimus concen- trations at the onset of the clinical symptoms and the improvement appeared only when the drug doses went down. Although recurrence of knee symptoms with an increase in tacrolimus dose would be much stronger proof of this association, it is not ethically justifiable. Furthermore, she was treated with verapamil in addition to other drugs for con- trolling hypertension. Verapamil might have played a part in a possible increased risk for this clinical complication, because it de- creases tacrolimus clearance. However, there are reports that calcium channel block- ers (albeit of the dihydropyridine type) can improve the bone pain syndrome.45

Although leg bone pain syndrome in kidney transplant patients who have received cyclosporin A is very rare, there are case reports described in the literature. To our knowledge, this is the first case of a renal transplant patient with pain in the lower limbs, related to tacrolimus treatment. Addi- tional case reports are needed to support this association.

CASE 1

A 42 year old man was admitted with an eight month history of arthritis and low back dyspnoea. Examination showed an acutely ill patient with a 39°C fever, oral ulcers, haemorrhagic gingival hyperplasia, bilateral haemorrhagic nasal discharge with crusted, diffuse necrotic purpura, neurtits, and black discoloration of some fingers and toes. The spleen was not palpable. Silent anterior myo- cardiac infarction was diagnosed because of raised MB-CK levels and ST-segment in- crease with loss of R waves in leads V1, V2, V3 on electrocardiogram. Antineutrophil cyto- plasmic antibodies (c-ANCA) were disclosed in serum and necrotising vasculitis was shown on skin biopsy specimen.5 No antiphospholi- pide antibody or coagulation protein abnormality could be disclosed. Treatment con- sisted of intravenous administration of prednisolone, cyclophosphamide, sodium heparinate, diltiazem, dinitrosorbide and enalapril. His short-term course was un- eventful. At day 14, the patient suddenly developed a severe haemorrhagic shock. Echotomography of the abdomen showed a splenic mass. At laparotomy, the spleen was almost disrupted by voluminous haematomata. Histological analysis of the spleen showed widespread necrotising vasculitis with haem- orrhagic infarction. After five years of follow up, the patient is in complete remission with oral cortimoxazole treatment.

CASE 2

A 23 year old young man was admitted in August 1996 because of repeated otitis media, sinusitis, epistaxis, headache, arthral- gia with fever and weight loss. Despite a short course of oral corticosteroids and antibiotics, his general condition worsened. Antiprotein- ase 3 c-ANCA were disclosed in serum. Chest computed tomography showed pulmo- nary nodules. Intranasal endoscopic biopsies demonstrated necrotising vasculitis with ephi- theloid and giant cells. Treatment included oral prednisone and intravenous cyclophos- phamide pulses. After a few days, serum creati- nine concentrations abruptly increased to 198 µmol/l and urine analysis showed micro- scopio haematuria and proteinuria. High dose methylprednisolone pulses were then given, intravenous cyclophosphamide was changed to a 100 mg daily dose of cyclophosphamide, the patient eventually achieved remission. In October 1996, abdomen computed tomogra- phy showed an intrapsilastic lesion that was consistent either with a splenic infarct or haem- orrhage (fig 1). The latter cause was marked by a WG flare in January 1997, which was complicated with massive thrombosis of the left iliofemoral vein and the inferior vena cava. No thrombophilic disorder could be found. Intravenous heparin treatment and anticoagulation with acenocoumarol were given. Because of persistent left hyphocripond tendon- derness, splenectomy was performed in Sep- tember 1997. Histological examination showed splen infarction with organised histo- ma-toma and sequelae of vasculitis (fig 2).

Spleen haemorrhagic infarction and hazards of anticoagulation in Wegener’s granulomatosis

In the largest cohort published to date, no splenic involvement is described in Wegener’s granulomatosis (WG). We report on two patients who required splenectomy for symp- tomatic spleen infarction in the course of WG.

COMMENT

Because they are vessels without collateral flow, occlusion of distal parenchymal splenic arteries leads invariably to splenic infarction. We have described necrotising vasculitis with haemorrhagic infarction. After five years of follow up, the patient is in complete remission with oral cortimoxazole treatment.
process. A severe splenic haemorrhage occurred in patient 1, which was clearly related to both necrotising vasculitis and hypocogulable state. Anticoagulation was indicated for inaugural myocardial infarction in case 1 and deep venous thrombosis in case 2, in both cases during active WG flare. Splenectomy was required in both our cases.

Our data suggest that antithrombotic treatment entails a specific risk of bleeding complications in patients with WG vasculitis. When anticoagulation is necessary in WG patients, computed tomography of the abdomen should be systematically performed and, if splenic infarction is disclosed, splenectomy should be considered.

THOMAS PAPO
DU FALLON-HUONG
JEAN-CARLES PIETTE
Internal Medicine, Hôpital Pitié-Salpêtrière, Paris, France

MARC ANDRE
OLIVIER AUMAÎRE
Internal Medicine, Hôpital Gébats, Clermont-Ferrand, France

FREDERIC CHARLOTTE
Histopathology, Hôpital Pitié-Salpêtrière, Paris, France

JEAN-LOUIS KEMENY
Histopathology, Hôpital Gébats, Clermont-Ferrand, France

Correspondence to: Dr T Papo, Internal Medicine Unit, Hôpital Pitié-Salpêtrière, 83 Boulevard de l'Hôpital 75651 Paris cedex 13, France.


13 Kettritz R, Anders S, Kettritz U, Schneider W, Gobel U, Luft FC. Spontaneous splenic hemorrhage in a patient with Wegener's granulomato-


Amiodarone induced lupus

Lupus related to amiodarone has not previously been described. We report on a patient who developed drug induced lupus (DIL) in association with amiodarone treatment. To our knowledge, this is the first report of amiodarone induced lupus (CD ROM: Medline, USA National Library: 1966–98).

A 51 year old white woman was admitted to our hospital because of two weeks of pleuritic chest pain, dyspnea on exertion, and non-productive cough. She had malaise, intermittent fever, arthralgia, and weight loss for more than six months. There was no history of Raynaud's phenomenon, oral ulcers or photosensitivity. She had a six year history of arterial hypertension and atrial fibrillation treated with amiodarone, digital and amiodarone (200 mg every two days) for the past two years.

Physical examination disclosed malar rash, an aortic systolic murmur (grade II/VI), and hyperventilation in both pulmonary bases. Laboratory studies showed an erythrocyte sedimentation rate of 90 mm 1st h. Peripheral blood examination revealed a mild normochromic and normocytic anaemia (10 g/dl), normal white blood cells count (4000/µl), and normal platelet count (180 000/µl). Coagulation tests were normal. All serum chemistries, including thyroid function tests, creatinine phosphokinase, immunoglobulins, complement levels, and urine analysis were within normal limits. Coombs's tests were negative. Rheumatoid factor was 1:320. Circulating immune complexes (IgG-C1q) were positive. Antinuclear antibodies (ANAs) were positive at 1:640; anti-Ro, anti-La, anti-dsDNA, anti-Sm, anti-histone antibodies, antiphospholipid antibodies, cryoglobulins, C reactive protein, VDRL and Mantoux test were negative. Blood and urine cultures were negative. Electrocardiogram was within normal limits, and the two dimensional echocardiogram showed mild aortic stenosis. Chest radiography revealed bilateral pleural effusions, without fibrosis or cardiomegaly. Pleural fluid was exudative, with lymphocytic predominance, without cytological features for malignancy. Cultures of pleural fluid for bacteria, including for Mycobacterium tuberculosis, were negative. Bone scan with technetium-99m showed increase uptake in hands, elbows, and knees. The histopathological examination of biopsy specimens of the skin, including indirect immunofluorescence stain, muscle and temporal artery did not show abnormal features.

The amiodarone was stopped and the patient progressively improved. No corticosteroids were given. On the third week she developed a transient relapse, with fever, malaise and with evidence of unilateral pleural effusion. One year after no clinical, analytical or radiological findings were present, and three years later she still remained free of symptoms, and the ESR, complete blood count, and radiological data were normal. The titre of ANA decreased but remained weakly positive at 1:40.

It is estimated that 3–7% of all patients with systemic lupus erythematosus (SLE) might have DIL. Clinical features of SLE and DIL are similar but there are certain distinguishing characteristics between them: the
patients with DIL are usually older; the prevalence of men and women is similar and the presenting symptoms are usually mild, with the patient usually complaining of malaise, fever and arthralgia, with or without arthritis, while skin, central nervous system or renal involvement is rare. Pleuroparenchymal disease is frequent and, as in classic SLE, anaemia and leucopenia may be present. Serum complement components are usually normal, ANAs are positive but anti-dsDNA and anti-Sm are negative, while anti-histones antibodies can be detected in most of patients.

The pathogenic mechanisms proposed for DIL include: cross reactivity between drug and the nucleic acid; hapten complex formation between drug and nucleic acid, or structural damage to the chromosomal DNA; action of drug as an adjuvant or immunostimulant, which, in concert with appropriate immune response genes, triggers polyclonal B/T cell activation; and interference with the complement pathway.

The incidence of side effects associated with amiodarone ranges from 40% to 91% and, in most of cases, these side effects are consequence of their potential to be directly toxic to several organ systems. **However, there is also some evidence of immunologically mediated phenomena related to amiodarone.** A positive skin and basophil degranulation tests with amiodarone, secretion of leucocyte inhibitory factor, positive lymphoblast transformation and circulation of a specific antibody of the IgG class have been described. **Moreover, several studies suggest that various biological and immunological markers of “systemic” disease activity are present in patients taking this drug. Circulating immune complexes, ANAs, and non-specific increase in ESR and white blood cell count, sometimes with eosinophilia, are common findings.**

Low ANA titre is not uncommon in an elderly patient. However, spontaneous SLE in elderly people is not usual and DIL must always be considered in the differential diagnosis. This case, presenting with malaise, fever, arthralgia, circulating immune complexes, and autoantibodies strongly suggests an immunological underlying condition. Moreover, this patient meets four SLE criteria: malar rash, serositis, haematological disorder (lymphopenia), and positive ANAs test. Imputability criteria of amiodarone induced lupus are present on a semiological basis with classic features of DIL and on a chronological basis with disappearance of most of the symptoms after amiodarone withdrawal. The relapse could be explained because of the long elimination half time of the drug and, in consequence, the immune response might progress despite discontinuation of the treatment.

**Antinuclear antibodies in relapsing polychondritis**

The prevalence of antinuclear antibodies (ANA) in relapsing polychondritis (RP) has been recently reported by Zeuner et al to be as high as 66%, usually in a low titre with a spreckled pattern. We report here on our experience of ANA testing in patients with RP.

The charts of 180 patients followed up in our institution fulfilling the criteria for RP proposed by Michet et al** have been recently retrospectively reviewed, with special focus on dermatological manifestations and their relation with myelodysplasia.** This aim led us to exclude 36 patients because the association of RP with potentially confounding diseases, such as systemic lupus erythematosus (SLE) present in nine, mixed connective tissue disease (MCTD) in five, rheumatoid arthritis in three, Takayasu arteritis in three, mesenteric panniculitis in three, spondyloarthritis in two, Crohn’s disease in two, psoriasis in two, or Lichen planus in two. Among the 144 patients remaining, 111 have been tested for ANA by using either Hep-2 cells or liver sections as substrate, or both. Most patients had repeated ANA determinations, including initial testing before onset of corticosteroid treatment, and the higher titres were considered for analysis. Figure 1 shows the histogram of ANA positivity according to titre.

We conclude that: (a) the prevalence of ANA observed in RP is low and, (b) as suggested by other authors the finding of a significant titre of ANA in a patient with RP strongly suggests the presence of an associated disorder, such as SLE, MCTD, Sjogren’s syndrome or acquired myelodysplasia.
There is no association between polymyalgia rheumatica and acute parvovirus B19 infection

Parvovirus B19 has been associated with a growing number of diseases. Besides the frequent manifestations such as erythema infectiosum and aplastic crisis in persons with increasing number of diseases. Besides the Parvovirus B19 has been associated with a parvovirus B19 infection.

Correspondence to: Dr J-C Piette.


Figure 1 Seroprevalence of IgG antibodies against VP1/VP2 (black bars) and NS1 (open bars) in control subjects and patients with polymyalgia rheumatica (PMR). The number of healthy controls in different versus the age matched control group was 22% (fig 1) and in patients with PMR 20% (p=0.057 versus the age matched control group).

Furthermore, we investigated the association between the presence of NS1 IgG antibodies and PMR related symptoms or laboratory parameters (patients with NS1 IgG antibodies were not different in age, sex, and medication). The symptoms were assessed using standard record forms from the medical histories (at the time serum was collected). We asked the patients for muscular pain in the left/right shoulder, left/right upper arms, left/right neck, left/right gluteal muscle, and left/right thigh. If one muscle group was painful the corresponding item was scored with one point (the sum of the item points was the overall muscle score). In PMR patients with NS1 IgG as compared with patients without NS1 IgG, arthralgia was more frequent (with versus without: 73% vs 40%; p=0.024). However, the overall muscle score was lower in NS1 positive than in NS1 negative patients (0.5 (0.2) SEM v 1.6 (0.3) SEM score points; p=0.021). With respect to other PMR related symptoms, no significant differences were found. In patients with a positive NS1 IgG antibody, interleukin 6 (4.6 (0.9) SEM v 11.3 (2.2) SEM; p=0.037) and soluble ELAM (48.2 (4.8) SEM v 71.4 (5.2) SEM; p=0.024) were significantly lower as compared with patients without NS1 IgG. Furthermore, disease related immune mediators such as interleukin 6 or soluble ELAM were lower in patients with as compared with patients without NS1 IgG. As a positive NS1 IgG indicates an active infection, an acute parvovirus B19 infection does not seem to be a pathogenic factor in our patients with PMR.

ANDREA HEMAUER SUSANNE MODROW Institute for Medical Microbiology and Hygiene, University Medical Centre Regensburg, Germany

JOACHIM GEORGI Department of Internal Medicine, Ostseeklinik, Damp, Germany

KLAS HELMKE Department of Internal Medicine IV, Hospital Munich-Bogenhausen, Germany

BERNHARD LANG Rheumazentrum Baden-Baden, Germany

JURGEN SCHOLMERICH RAINER H STRAUB Department of Internal Medicine I, University Medical Centre Regensburg, Germany

Correspondence to: Dr R H Straub, Department of Internal Medicine I, University Medical Centre, D-93042 Regensburg, Germany.


5 Moro N, Standaard T, Young NS. A review of 110 PMR patients (patients 11.3 (2.2) SEM; p=0.037) and soluble ELAM (48.2 (4.8) SEM v 71.4 (5.2) SEM; p=0.024) were significantly lower as compared with patients without NS1 IgG. No significant differences were found with respect to erythrocyte sedimentation rate, C reactive protein, tumour necrosis factor, interleukin 2, and interleukin 1B.

In view of these data, there was a positive association between NS1 and arthralgia. However, other symptoms and parameters of inflammation such as erythrocyte sedimentation rate were not associated with the presence of NS1 IgG. Furthermore, disease related immune mediators such as interleukin 6 or soluble ELAM were lower in patients with as compared with patients without NS1 IgG. As a positive NS1 IgG indicates an active infection, an acute parvovirus B19 infection does not seem to be a pathogenic factor in our patients with PMR.
Neutrophil chemotaxis in Behçet’s syndrome

It has been suggested that the marked cellular inflammatory response, which characterises Behçet’s syndrome (BS), may be attributable to increased neutrophil locomotion. However, others disagree. We have re-evaluated chemotaxis of polymorphonuclear leucocytes (PMNs) in BS among a greater number of patients in a controlled setting. Fifty four male BS patients, nine male patients with ankylosing spondylitis, eight with psoriasis and 37 male healthy controls were studied with 28 female patients with BS and 16 healthy female controls. Behçet patients with severe disease were those with active major vessel and/or eye involvement. We measured chemotaxis with the “under the agarose method”. The measurements were masked with the assessors not knowing the diagnoses. An inverted microscope fitted with an ocular micrometre disc to measure the migration of neutrophils from middle wells to outer (chemotaxis) and inner wells (chemokinesis) was used. Zymosan activated sera (patients or controls) were used as a source of C5a. Results were expressed as micrometre square (1 mm²=8 squares). Additively the plates were evaluated macroscopically for observation of the migration between neutrophil wells.

Tables 1 and 2 show the results. There were no significant differences between the chemotactic indices of the various groups of patients and controls studied of either sex. Maximal chemotaxis rates in the groups varied from 67% to 100%.

There is marked heterogeneity in disease expression in men and women in BS and we re-examined that some of the confusion in the literature about neutrophil activity might be related to this. Thus we analysed our data separately for either sex. Although there was a tendency for male patients with severe disease to have higher C5a. Results were expressed as micrometre square (1 mm²=8 squares). Additional the plates were evaluated macroscopically for observation of the migration between neutrophil wells.

Not a regular feature of ocular BS (personal communication).

In vivo assays do not differentiate chemotaxis from chemokinesis. In the Carletto study clinically active Behçet patients demonstrated increased chemotaxis to sera by Senn’s modified in vivo assay. Others had found hyperchemotaxis to might have been responsible fractions again by using an in vivo assay. Although it is difficult to compare the results of in vitro and in vivo assays, we thought these reported increases might have resulted from increased chemokinesis. In our experiments we observed maximal chemotaxis (3 mm) frequently, however, we did not find any significant differences in chemotactic indices between diseased and healthy subjects.

An interesting aspect of our study was the migration between neutrophil wells that was observed in many of the Petri dishes. This was observed even though we had not used cellular materials as chemotactic agents. Presumably the gravity of the cellular materials overcame the chemical gradient of zymosan activated sera in some Petri dishes. Because of the observed migration between neutrophil wells, we suggest that there should be only one “triple well rank” in a Petri dish. On the other hand our method of preincubation of the whole blood for 45 minutes at 37°C before harvesting the PMNs (intended for better viability) might have been responsible for this phenomenon by increasing the chemotactic activity in all groups studied. Further studies are needed to clarify these issues.

<table>
<thead>
<tr>
<th>Table 1 Chemotactic indices in men*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Groups</td>
</tr>
<tr>
<td>Behçet’s</td>
</tr>
<tr>
<td>Severe Behçet’s</td>
</tr>
<tr>
<td>Ankylosing spondylitis</td>
</tr>
<tr>
<td>Psoriasis</td>
</tr>
<tr>
<td>Healthy controls</td>
</tr>
</tbody>
</table>

*Kruskal-Wallis one way analysis of variance, corrected for ties: p≥0.22 (81), DF=4, p>0.05.

<table>
<thead>
<tr>
<th>Table 2 Chemotactic indices in women*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Groups</td>
</tr>
<tr>
<td>Behçet’s</td>
</tr>
<tr>
<td>Healthy controls</td>
</tr>
</tbody>
</table>

*one tailed, p<0.05.

Letters, Matters arising

Neuropsychiatric systemic lupus erythematosus

The considerable difficulties in making sense of the literature on patients with lupus involving the central nervous system are re-emphasised in the paper by Rood et al. The authors, who hope to be fair take a sensibly cautious approach to their results, nevertheless seek to persuade us that the IL10 locus is associated with neuropsychiatric lupus on the basis of a historical case notes review of 42 patients with neuropsychiatric disease, compared with 50 who lacked such involvement.

Their conclusion needs to be treated with caution. Does it make sense to lump together 42 highly diverse patients and make the kind of claim they have made? The authors suggest that CNS lupus is attributable to either antiphospholipid antibody related thrombotic events, or “immune mediated” disease. This division is artificial. There is a considerable variability in CNS lupus that proposes that a wide variety of immunopathogenic mechanisms may be responsible in individual cases. These mechanisms include thrombotic effects, which may be linked to antiphospholipid antibodies, a true vasculitis, a cross reaction between antibodies that recognise the lymphocyte surface targets and neurologol antigens, and antiphospholipid antibodies to a wide variety of neurological targets. A considerably larger number of patients will have to be studied before any claims of links to an IL10 promoter haplotype can be truly convincing.

We agree with the authors that patients with SLE have a higher innate production of IL10 than controls. However, as there is no significant difference in the frequency of the IL10 promoter single nucleotide polymorphism (SNP) in SLE patients when...
compared with controls in their study, we suspect that the difference in IL10 production in terms of the IL10 SNP alleles frequencies. Differences have been described with respect to microsatellites and one awaits confirmation from other populations or family studies. To our knowledge, a difference in IL10 production between patients with neuropsychiatric disease SLE and non-neuropsychiatric disease SLE has not been described. The described associations would be biologically meaningless if IL10 production is similar between these two groups. The authors suggest that the -1082A allele is associated with a higher innate IL10 production, however, they appear to ignore the only published study to date that showed that the A allele was associated with lower IL10 production. In addition we have confirmed that the A allele is associated with lower IL10 production in transient transfection studies and the ATA/ATA genotype is associated with low IL10 production in whole blood culture. The increase in the A allele is mainly accounted for by an increase in the ATA haplotype in their neuropsychiatric disease patients and therefore they are described with a low IL10 producing haplotype, not a high IL10 producing haplotype. One interpretation of this would be that patients with neuropsychiatric disease symptoms are unable to adequately control inflammation from a variety of different pathalogical mechanisms because of low IL10 production.

DAVID ISENBERG
Centre for Rheumatology, UCLH, London

ESTHER CRAWLEY
Department of Molecular Pathology, UCLMS

PAT WOO
Department of Molecular Pathology, UCLMS

4 Crawley E, Kay R, Silibourne J, Patel P, Hutchinson IV. They describe how six months after initial presentation the diagnosis of adult onset Still’s disease (AOSD) was made and despite regular review at several centres, this diagnosis was upheld for a further five years. Multiple investigations were performed adding little to the original diagnosis. It is not mentioned whether a serum ferritin was taken. This may have been useful given the initial diagnosis of AOSD as it might have resulted in questioning this diagnosis, permitting an earlier diagnosis of Whipple’s disease. It is widely reported in the literature, as far back as 1975, that increased serum ferritin may be of use in both diagnosis and monitoring of AOSD. Hyperferritaemia is not however exclusive to AOSD, as various malignancies, hepatic necrosis and haemachromatosis can all cause it. However, values up to 25 000 µg/l have been described in AOSD and reportedly, values rarely exceed 3–5000 µg/l in the above conditions. The pathogenesis is not clearly understood, but it has been hypothesised that in AOSD, cytokine upregulation of ferritin mRNA
translational control of ferritin synthesis and iron overload syndromes. A comparative study of diagnostic criteria in adult-onset Still's disease (AOSD) by Mason et al suggest the Yamaguchi criteria are superior to the others tested, including Cush et al quoted by Knight and Symmons. However, none of the criteria to aid diagnosis make use of serum ferritin measurement despite the claims for its use in the literature and acceptance in clinical practise. Although undoubtedly useful if very high, it is not clear what the relevance of a normal value in AOSD is, in a case satisfying clinical diagnostic criteria (although we have never seen such a case). In rare diseases such as AOSD, it is difficult to assess and evaluate diagnostic criteria and calculate sensitivity and specificity of possible disease markers. If serum were stored on this patient it would be interesting to know the serum ferritin measurement and how, if at all, it would have affected this patient’s management.

MARK QUINN

ANDREW GOUGH

Department of Rheumatology, Old Home, Leeds General Infirmary, Great George Street, Leeds, West Yorkshire, LS1 3EX.

Correspondence to: Dr M A Quinn.

References

Cladribine in the treatment of systemic lupus erythematosus nephritis

VLASSIS KONTOGIANNIS, PETER C LANYON and RICHARD J POWELL

*Ann Rheum Dis* 1999 58: 653
doi: 10.1136/ard.58.10.653

Updated information and services can be found at:
http://ard.bmj.com/content/58/10/653.1

These include:

**References**

This article cites 5 articles, 0 of which you can access for free at:
http://ard.bmj.com/content/58/10/653.1#BIBL

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/